Skip to content
Blackberry Empire – Lifestyle
Author:
Marengo Therapeutics
Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development
September 9, 2026
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
August 4, 2026
Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board
July 20, 2026